FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists3
טרם מתן מרשם נא לעיין בעלון לרופא כפי שאושר ע”י משרד הבריאות
*FASENRA SIGNIFICANTLY REDUCES ANNUAL EXACERBATION RATE VS PLACEBO WHEN GIVEN AS ADD-ON THERAPY (P<0.0001, P=0.0188)1,2
† Improvements in pre-bronchodilator FEV1 were present within 4 weeks of treatment start (in the Q8W cohort) and were maintained throughout the entire treatment period vs placebo (p<0.05)1,2
Exacerbations were defined as a worsening of asthma requiring the use of systemic corticosteroids for ≥3 days, or an emergency department or urgent care visit requiring use of OCS, or hospitalization. For patients on maintenance OCS, an exacerbation requiring OCS was defined as a temporary increase in stable, background dosage of OCS for ≥3 days or a single depo-injectable dose of corticosteroids.1,2
1. Bleecker ER, et al. Lancet 2016;388(10056):2115–27. 2. FitzGerald JM, et al. Lancet 2016;388(10056):2128–41.
3. Fasenra® 30 mg [package insert]. Israel: Astrazeneca (Israel) Ltd.; 2018.
IL-0674 Expires: June 2021
אסטרהזניקה ישראל בע”מ, רח’ החרש 6, ת.ד. 1455 , פארק מגדלי הוד השרון E, הוד השרון 452407
